PURPOSE Evidence-based guidelines recommend cascade genetic counseling and testing
for hereditary cancer syndromes, providing relatives the opportunity for early detection and …

Pathogenic genetic variants (formerly called mutations) present in the germline of some
individuals are associated with a clinically relevant increased risk of developing lung cancer …

Nearly 3% of the population carries genetic variants that lead to conditions that include
hereditary breast and ovarian cancer and Lynch syndrome. These pathogenic variants …

Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA
carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of …

Population genomic screening to detect carriers of rare monogenic variants for medically
actionable conditions is supported by substantial evidence of clinical utility and cost …

Importance Pathogenic variants (PVs) inBRCA1, BRCA2, PALB2, RAD51C, RAD51D, and
BRIP1cancer susceptibility genes (CSGs) confer an increased ovarian cancer (OC) risk …

Recent advances in the detection of germline pathogenic variants (PVs) in BRCA1/2 genes
have allowed a deeper understanding of the BRCA-related cancer risk. Several studies …

Germline mutations in cancer-susceptibility-genes (CSG) can dramatically increase
womens' lifetime risk of ovarian, endometrial, breast and bowel cancers. Identification of …

Genomic medicine is expanding from a focus on diagnosis at the patient level to prevention
at the population level given the ongoing under-ascertainment of high-risk and actionable …

Purpose To evaluate rates of familial disclosure of hereditary cancer syndrome information.
Methods A systematic review and meta-analysis was conducted in accordance with PRISMA …